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AbstrACt
Introduction Hospitalised older patients frequently suffer 
from inadequate sleep, which can lead to patient distress 
and delayed recovery from acute illness or surgical 
procedure. Currently, no evidence-based treatments 
exist for sleeping problems in hospitalised older patients. 
Benzodiazepines, such as temazepam, are regularly 
prescribed by physicians, although they have serious 
side effects; for older patients in particular. Melatonin is 
proposed as a safe alternative for sleeping problems in 
hospitalised older patients, but the efficacy of melatonin is 
unclear in this population. Therefore, the aim of this study 
is to investigate the effects of melatonin and temazepam 
compared with placebo on sleep quality among 
hospitalised older patients with sleeping problems.
Methods and analysis This study is a multicentre, 
randomised, placebo-controlled trial. A total of 663 
patients will be randomised in a 1:1:1 fashion to receive 
either melatonin (n=221), temazepam (n=221) or placebo 
(n=221). The study population consists of hospitalised 
patients aged 60 years and older, with new or aggravated 
sleeping problems for which an intervention is needed. 
The primary outcome is sleep quality measured with the 
Leeds Sleep Evaluation Questionnaire (LSEQ). Secondary 
outcomes include sleep parameters measured with 
actigraphy and medication-related adverse effects.
Ethics and dissemination This study was approved by 
the Medical Ethics Committee of the Academic Medical 
Centre Amsterdam, (No 2015_302). Study findings will be 
disseminated through presentations at professional and 
scientific conferences and publications in peer-reviewed 
journals.
trial registration number NTR6908; Pre-results.
IntroduCtIon
background
Hospitalised older patients frequently expe-
rience sleeping problems due to medical, 
psychological or environmental disturbances. 
The prevalence of sleep problems among 
older patients in medical and surgical wards 
varies between 30% and 65%.1–3 Apart from 
the feeling of tiredness, insufficient sleep 
has substantial consequences for hospital-
ised patients. This includes delayed recovery 
from acute illness or surgical procedures 
because of its immunosuppressive effect,4 5 
risk of delirium and falls6–9 and disturbances 
in metabolic and endocrine functioning.10 11 
Thus, adequate treatment of sleeping prob-
lems is necessary. Today, it is still unclear how 
sleeping problems should be treated in the 
hospital. Non-pharmacological interventions 
are advised as first choice therapy in hospital-
ised patients,12–14 but there is limited evidence 
to support the effectiveness of non-phar-
macological interventions.15 With regard to 
pharmacological interventions, there is insuf-
ficient evidence to support its effectiveness for 
improving quality or quantity of sleep in hospi-
talised patients suffering from poor sleep.16
Currently, up to 29% of older hospitalised 
patients with sleeping problems receive benzo-
diazepines,17 18 despite a recent meta-analysis 
of risks and benefits for short-term treatment 
of insomnia, which stated that benzodiaze-
pines have little effect and may not outweigh 
strengths and limitations of this study
 ► The results of this study will provide knowledge 
relevant for clinical practice and fill gaps in current 
guidelines concerning sleep problems in hospital-
ised older patients.
 ► To optimise the generalisability of the findings, this 
is a multicentre study with participants from differ-
ent wards and minimal exclusions criteria.
 ► This study investigates, next to the effects, also the 
adverse events of melatonin and temazepam com-
pared with placebo.
 ► Patients with cognitive impairment are excluded due 
to ethical considerations, even though these vulner-
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the risks of adverse events, especially in a high-risk older 
population.19 Older patients have a higher risk of adverse 
drug events from benzodiazepines due to altered phar-
macokinetics and pharmacodynamics. Common adverse 
drug events include in-hospital falls, delirium, aspira-
tion and respiratory depression.20 21 Furthermore, use 
of benzodiazepine during hospitalisation can lead to 
prolonged use at home, which might promote chronic 
use and substance-dependency.22
The neuroendocrine hormone melatonin has been 
proposed as a safer alternative to improve sleep quality 
because of its limited side effects.8 23–25 Melatonin, produced 
by the pineal gland at night, is well known to influence circa-
dian rhythm and sleep.26 Two randomised control trials 
(RCTs) investigated the effectiveness of melatonin compared 
with placebo in older community dwelling persons with 
chronic insomnia and found that melatonin improved sleep 
quality significantly.27 28 However, studies on the effectiveness 
of melatonin for sleeping problems in acute hospitalised 
older patients are scarce. Three RCTs have been performed 
in adult patients on the intensive care unit,29–31 showing 
inconsistent results; one out of three reported a positive 
effect of melatonin.30 All three studies were underpowered 
and none specifically assessed older patients with predefined 
sleep related problems.
Only one small RCT investigated the effectiveness of 
melatonin on a general medical ward in adults, which 
resulted in beneficial effects for melatonin compared 
with placebo on the sleep onset latency and patient 
satisfaction.32
The overall aim of this study is to establish an evidence-
based pharmacological treatment for hospitalised older 
patients with sleeping problems. In this study, we will first 
hypothesise that melatonin and temazepam are more 
effective than placebo on sleep quality among hospital-
ised older patients with sleeping problems and second 
melatonin is more effective than temazepam.
objectives
The primary objective is to investigate first the effects 
of melatonin and temazepam compared with placebo 
among hospitalised older patients on self-reported sleep 
quality. Second, to investigate if melatonin is more effec-
tive than temazepam.
The secondary objectives are to investigate the effects 
of melatonin, temazepam and placebo on:
1. Other self-reported sleep parameters: getting to 
sleep, awakening from sleep, behaviour following 
wakefulness.
2. Objective sleep parameters: reduction in sleep onset 
latency, sleep efficiency, number and duration of wake 
bouts, time awake after sleep onset.
3. Adverse events related to study medication: incidence 
of delirium, cognition, number of falls, complications.
4. Length of hospital stay in days.
5. Time needed to reach improvement in self-reported 
sleep quality.
6. Proportion of good nights of sleep during study period.
MEthods
trial design
This study is a multicentre, randomised, placebo-con-
trolled trial. Figure 1 shows the trial design summary. This 
study will be conducted in two university teaching hospi-
tals and in two teaching hospitals in the Netherlands: the 
Academic Medical Centre (AMC) Amsterdam, the Univer-
sity Medical Centre Groningen (UMCG), Gelre Hospitals 
Apeldoorn and the Medical Centre Leeuwarden (MCL). 
The design of this trial protocol has followed the recom-
mendations of the SPIRIT 2013 statement.33
Patient and public involvement
Senior citizens were involved in several stages of this 
project, including the relevance of the study, developing 
the research question, the study design and conduct of 
the trial. The older representatives (Denktank 60+) part-
nered with us on the information material, the ques-
tionnaires and the burden of the questionnaires from a 
patient perspective. Once the trial has been published, 
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participants will be informed of the results in a study 
newsletter suitable for the public.
Eligibility criteria
Eligible participants must have the following 
characteristics:
1. 60 years or older.
2. Admitted to the hospital for a medical or surgical rea-
son.
3. Experiencing or complaining about new onset or ag-
gravated sleep problems during hospital admission, for 
which a pharmacological intervention is needed based 
on the judgement of the attending physician.
4.  Ability to fill out a sleep questionnaire.
People with the following characteristics are not 
eligible:
1. Inability to speak, understand or write Dutch.
2. Lack of decision-making capacity.
3. Previously diagnosed dementia.
4. Transferred from another hospital to one of the study 
centres, with insufficient information on previous use 
of sleep medication.
5. Expected stay in hospital of <48 hours.
6. Concurrent use of sedative for a sleeping disorder 
(>2 dosages in the last week), such as benzodiazepine, 
non-benzodiazepine (Z-drugs) or melatonin.
7. Alcohol consumption >13 units/week for women 
and >20 units/week for men.
8. Drug interactions with melatonin or contraindications 
for benzodiazepine use.
First selection of eligible patients will be done by the 
attending physician, if eligible the physician will inform 
the research team. Final selection will be done by a 
member of the research team, who also will recruit eligible 
participants and include them after written informed 
consent for participation has been obtained.
randomisation and blinding
After patients have given informed consent, participants 
will be allocated randomly to either temazepam, mela-
tonin or placebo capsules (ratio is 1:1:1). Randomisation 
is stratified per centre and department, the strata include 
the four centres (AMC, Gelre hospitals Apeldoorn, MCL 
and UMCG) and departments (surgical vs medical). A 
stratified block randomisation made by an independent 
statistician is used and generated by the programme 
CASTOR Electronic Data Capture (Castor EDC, Ciwit BV, 
Amsterdam, the Netherlands, 2017). The researchers are 
not informed about the block sizes.
All medication used in the study will appear identical to 
ensure true blinding of the patient, attending physician, 
nurse and investigators. The study medication is manufac-
tured by Tiofarma, Oud-Beijerland, the Netherlands and 
will be distributed to the study sites’ pharmacies. Study 
medication must be kept intact at all times; the capsules 
cannot be broken. All study medication is packed in 
Single Unit Supply packages, blinded and dispensed by 
site trial pharmacists. The dispensing pharmacist will 
record the patient, patient ID and assigned medication by 
the randomisation process. Storage, delivery, dispensing 
and destruction of medication will adhere to Good Clin-
ical Practice regulations (ICH-GCP).34
At the end of the study, when all data are collected, the 
data manager will lock the database. The information of 
the study arm (melatonin, temazepam and placebo) will 
be masked by the data manager, after which analysis can 
be performed in a blinded way by the researchers. Rando-
misation method will be broken when the study team has 
declared the data analysis finished.
In case of emergencies or urgent situations, such as 
anaphylactic reactions or loss of consciousness, and 
knowledge of the actual treatment is essential for further 
patient management, the blinding of the treatment of an 
individual participant can be broken (unblinded). In this 
case, the attending physician will contact the trial phar-
macist to disclose the blinding of the study treatment for 
this individual patient.
Intervention
After randomisation, all participants receive the allocated 
medication once daily which is in the evening before 
sleep (ante noctem). Study medication will be adminis-
tered orally starting on the day of study enrolment.
Melatonin 1 mg and temazepam 10 mg will be used 
as study medication. The dosage of 1 mg melatonin is 
chosen based on a recent systematic review, to best mimic 
the normal physiological circadian rhythm of melatonin 
by avoiding prolonged supra-physiological blood levels in 
case of higher dosages.35 The dosage of 10 mg temazepam 
is the recommend dose for older patients.36
Study medication will be continued to either a maximum 
of 10 days, or 12 hours before hospital discharge, or after 
three consecutive nights of good sleep, or until partici-
pant decides to withdraw from the study. In case sleep 
problems do not resolve with study medication, the dosage 
can be doubled. This decision will be left to the patient’s 
attending physician. Attending physicians are instructed 
only to consider a double dose when the patient has slept 
badly for two nights in a row, in case there are no environ-
mental or treatable physical factors that could cause the 
poor quality of sleep (QOS) and they should take possible 
adverse effects of study medication into account. Double 
doses of study medication will be registered in the case 
report form and in the medical record.
Study medication will be discontinued if a condi-
tion occurs that needs treatment with benzodiazepines 
(eg, anxiety), if events occur that imply a higher risk of 
adverse events (eg, respiratory insufficiency or starting 
chinolones) and in case of persisting sleeping problems. 
Persisting sleep problems is defined as self-reported poor 
QOS for three consecutive nights after study medication 
has been doubled.
After study medication is discontinued, either due 
to a reason listed above or due to end of study period, 
treatment will be provided according to the hospital’s 
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physician. Patients remain in the study and follow the 
study protocol, except for using study medication.
timing of measurement and outcome measures
Demographic data, such as age, sex, nationality, highest 
educational status and living situation will be collected 
at baseline. Medication use, blood tests 24 hours prior to 
study inclusion or 24 hours after study inclusion, severity 
of foregoing sleep problems, depression and anxiety, level 
of independence, health status and vulnerability (eg, fall 
risk) are measured at baseline. Primary and secondary 
outcome measures will be recorded at baseline (T0) and 
every day until the 10th day (T1–T10) or until discharge. 
Table 1 provides an overview of the timing of measure-
ments and the outcome measures.
Primary outcome
The primary outcome of the study is change in self-re-
ported sleep quality during the treatment period (T0–
T10). Sleep quality will be assessed with the Leeds Sleep 
Evaluation Questionnaire (LSEQ).37 38
Secondary outcomes
1. Change in self-reported sleep measures: getting to 
sleep, awakening from sleep and behaviour following 
wakefulness during treatment period will be assessed 
with the other subscales of the LSEQ. These measures 
will be assessed on T0 until T10.
2. Objective sleep parameters. To assess objective sleep 
parameters participants will wear a MotionWatch eight 
during the study period (T0–T10). This wristwatch-like 
device will calculate sleep latency, sleep efficiency, 
number and duration of wake bouts, time awake after 
sleep onset in minutes based on motion of the patient.
3. Number of good night sleep. Good nights of sleep 
will be assessed with a numeric rating scale for QOS. 
On the numeric rating scale ≤4 is considered a bad 
night’s sleep, 5–6 is neither a good or bad night’s sleep 
and ≥7 is a good night’s sleep.39
4. Time needed to reach improvement in self-reported 
sleep quality will be based on the LSEQ as well. Im-
provement of sleep quality is defined as the first day 
that an improvement of 10 mm is reached compared 
with baseline.
5. Adverse events defined as confusion, delirium, reduced 
consciousness, falls, aspiration and other additional 
adverse events will be monitored daily on T0–T10.
6. Length of hospital stay in days will be recorded at 
discharge.
To ensure consistency and optimisation of the data 
collection process, all members of the research team who 
will include patients in the study will follow a training how 
to conduct measurements according to Standard Oper-
ating Procedures and how to fill out the Case Report 
Forms. Non-adherence to the study protocol will be obvi-
ated as much as possible. However, when it occurs this will 
be registered by the research team.
sample size calculation
Sample size calculation is based on the primary outcome 
measure QOS, assessed with the LSEQ. To establish a 
clinically relevant observed effect of melatonin, temaz-
epam or placebo a difference of 10 mm on the QOS 
was chosen.40 The SD was calculated based on the SE 
presented in this study. To detect a mean difference of 
10 mm, two-sided, with a power of 80% and significance 
level of α<0,05, we need at least 210 patients per group 
(total of 630 patients).
The expected dropout rate during study period is 5%.41 
Therefore, we should recruit at least 663 patients, with 
221 patients in each study arm.
data analysis
Data will be analysed according to an intention-to-treat 
principle. Researchers are not aware of the alloca-
tion of the intervention and therefore analyses will be 
conducted in a blinded way. A per-protocol analysis will 
be conducted excluding patients that did not receive 
the intervention according to protocol and were incor-
rectly included in the study. To determine the effects of 
temazepam, melatonin or placebo on sleep quality, linear 
mixed models will be used. Analysis will be performed on 
change of sleep quality over time taking baseline value 
into account (ie, night before start of study medication). 
The following covariates will be added to the model: age, 
gender, different concurrent medication (eg, morphine), 
severity of disease diagnosis (Rotterdam Symptom Check-
list (RSCL), pain severity (visual analogue scale, RSCL), 
acute or elective admission to the hospital, foregoing 
sleep problems (insomnia severity index), number of 
patients in the room, level of independency (Katz Index 
of Independence in Activities of Daily Living), level of 
anxiety (Hospital Anxiety Depression scale) and days in 
the hospital before inclusion. Linear mixed models will 
also be used to evaluate getting to sleep, awakening from 
sleep, behaviour following wakefulness and the objective 
sleep parameters measured with actigraphy. Analyses of 
the time needed to reach improvement of sleep quality 
will be done with an interval-censored survival analysis. 
Proportion of good nights of sleep measured with the 
numeric ratings scale will be analysed, when normally 
distributed, with multiple linear regression analysis. For 
the analysis of adverse events related to study medication, 
descriptive statistics will be used to show which adverse 
events occurred. Depending on the occurrence of these 
adverse-events and distribution, log-linear analysis, 
Poisson or multiple regression analysis will be used. Time 
to occurrence of an adverse event will be analysed with 
Cox regression.
data management
All participants are assigned a specific trial number, and 
all data will be entered in an electronic trial-specific data-
base. The data entry process will be documented and 
produce an audit trail. The database will be stored and 
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Table 1 Overview of the timing of measurements and outcome measures
Measurement Description and instrument
Timepoints
Baseline Daily Discharge
Sleep quality Leeds Sleep Evaluation Questionnaire (LSEQ),38 44 10-item 
questionnaire, self-rated, on 0–100 mm line. Validated tool for 
measuring changes in sleep on four domains; getting to sleep, quality 
of sleep, ease and awakening from sleep and alertness and behaviour 
following wakefulness
The Dutch version of the LSEQ is forwards and backwards translated 
according to the translation guidelines45
x x
Numeric rating scale for overall sleep, an overall numeric rating of 
quality of sleep. With ‘0’ representing a very bad night’s sleep and ‘10’ 
representing a very good night’s sleep 
x x
Sleep pattern The core consensus sleep diary46, a 10-item sleep log to gain insight in 




Based on literature,15 47–50 an overview is made of 10 influencing factors 
on sleep in hospitals. Participants can indicate whether these factors 




Actigraphy, MotionWatch 8, a wristwatch-like device, worn on the non-
dominant hand. The actiwatch registers motion in epochs of 30 s. Based 
on motion sleep latency, sleep efficiency, number and duration of wake 
bouts, time awake after sleep onset in minutes can be calculated
x x
Cognition Mini-Mental State Examination51, a 10-item screening tool to evaluate 
global cognitive function
x x*
Stroop Colour-Word test52 53, consists of three subtasks. Used to 
measure attention, processing speed, cognitive flexibility and working 
memory
x x*
The Trail Making Test (TMT) A&B54 55, consists of two subtasks, is used 





4 AT,56 a four-item screening tool to detect attention deficits due to 
delirium
x x†
DSM-V,57 the Diagnostic and Statistical Manual of the American 
Psychiatric Association (DSM-5) the most widely used nomenclature by 
clinicians and researchers for the classification of delirium
x‡ x‡ 
Severity of sleep 
problems
Insomnia severity index,58 a seven-item questionnaire, self-rated, to 




Hospital Anxiety Depression scale59, a 14-item questionnaire, self-rated, 





Katz-15 Activities of Daily Living (ADL) index scale,60 61 the modified Katz 
ADL index 15-item scale, answered with ‘yes’ or’ no’ to evaluate the 
level of independence
x
Health status Rotterdam symptom check list (RSCL)62, a 30-item questionnaire, self-
rated, to assess physical and psychological symptom
x x§
Charlson comorbidity index (CCI),63 a classification method for comorbid 
conditions. It is a valid method to estimate risk of death comorbid 




Safety management system patient screening64 x
Adverse events Confusion, delirium, reduced consciousness, falls, aspiration, other 
additional adverse events (in complication register) and length of 
hospital stay in days
x
*On day 3 Stroop Colour-Word test and TMT are repeated with daily assessment.
†Administered if a delirium is suspected.
‡When score on 4AT deviates, detailed assessment of mental status with DSM-V to reach diagnosis of delirium.
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regulations34 and the European Data Protection Direc-
tive. Confidentiality of participant information will be 
maintained throughout the trial. Results can only be 
traced to participants by the researchers involved. Data 
will be stored for a period of 15 years after the study has 
ended, according to ICH-GCP regulations.34
Participant safety and monitoring
This trial is considered a low-risk study. Melatonin in a 
dosage of 1 mg is not known to show any adverse events and 
is considered safe for use by older patients. Temazepam has 
potential adverse-effects but this medication is part of usual 
treatment of hospitalised older patients with sleep prob-
lems, participation in the study will not expose patients to 
any additional risks. Close monitoring of all possible adverse 
events related to study medication will take place, and in case 
any adverse events occur, appropriate measures will be taken 
in consultation with the attending physician. The Clinical 
Research Unit (CRU) of the AMC will conduct the moni-
toring of this trial in compliance with the Medical Research 
Involving Human Subjects Act (WMO) and ICH-GCP regu-
lations.34 Annual reports of the study progress will be sent 
to the Medical Research Ethics Committee of the Academic 
Medical Centre Amsterdam. As this trial is considered as a 
low risk study with a low risk on serious adverse events, no 
Data and Safety Monitoring Board (DSMB) will be installed 
or interim analysis performed.
dIsCussIon
Although sleeping problems are a common complaint in 
hospitalised older patients, there is still no evidence based 
pharmacological treatment available. Most studies on (non-)
pharmacological treatment of sleeping problems in older 
patients were performed in community dwelling older 
people. However, sleep quality in hospitalised elderly is 
influenced by other factors than community dwelling older 
people and might require other therapeutic regimes.42 For 
example, light and noise in the room influences the QOS 
in hospitalised older patients and it is difficult to measure, 
subsequently standardise for these confounders on the 
ward. In order to minimise the effect of these potential 
confounders, we stratified randomisation, in which patients 
are randomised by hospitals and departments. In this way, 
the known and unknown confounders are randomised and 
equally distributed among the groups.
In this study it was not possible to measure sleep quality 
and quantity using polysomnography, which is the gold 
standard to measure sleep quality and quantity. Instead 
of polysomnography, we measured objective sleep param-
eters indirectly by using an actigraphy, in addition to the 
self-reported sleep outcome measures.
This study is the first large randomised controlled trial 
on the effects of melatonin, temazepam or placebo in 
hospitalised older patients, which aimed to establish an 
evidence based pharmacological treatment for sleeping 
problems in older hospitalised patients. Irrespective of 
the results of this trial, the outcomes can be used for 
developing clinical guidelines for the treatment of sleep 
problems among hospitalised older patients.
EthICs And dIssEMInAtIon
The trial will be conducted in accordance with the Decla-
ration of Helsinki 1996 and principles of good clinical 
practice. Any substantial protocol amendments will be 
submitted to the ethics committee. A register of protocol 
amendments will be made available in the study protocol.
The grant was an unrestricted grant from the University 
of Amsterdam Foundation.
Trial methods and results will be reported according 
to the Consolidated Standards of Reporting Trials 2010 
guidelines.43 The study findings will be published in rele-
vant peer-reviewed journals.
trial status
The trial has started on 29th of January 2018.
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